Parliamentary Panel Recommends Review of Medicine Pricing and Cost-Based Pricing Feasibility
A Parliamentary Standing Committee has recommended reviewing the pricing framework for non-scheduled medicines, which constitute about 82% of the pharmaceutical market, to prevent arbitrary price fixation. The panel suggested exploring the reintroduction of cost-based pricing, previously replaced by market-based pricing under the 2013 Drugs (Prices Control) Order, especially where significant price disparities or high mark-ups exist. The government defended the current market-based system, citing its role in encouraging investment and innovation, while the committee also called for revising policies to reflect industry changes.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (49/100). Lens Score 56/100.
Outlets measured: thefinancialexpress, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 6 Aug, 06:34 pm. Other outlets followed.